Reports and Insights (R&I) has published a new report titled, “Varicella Zoster Infection Treatment Market: Opportunity Analysis and Future Assessment 2020 to 2028”
Global Varicella Zoster Infection Treatment Market, by Drug Type (Acyclovir, Valacyclovir, and Famciclovir), by Route of Administration (Oral, Topical, and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.
The global varicella zoster infection treatment market in 2020 is estimated for more than US$ 1.5 Bn and expected to reach a value of US$ 2.1 Bn by 2028 with a significant CAGR of 4.5%
As per the report, the varicella zoster infection treatment market is expected to witness steady growth, owing to the increasing geriatric population across the globe, growing cases of chronic ailments like cancer and cardiac disease, growing awareness among patients, and the increasing investments in clinical innovation.
However, the proactive measures, the invention in medical processes including, 3-D printing, blockchain, and robotic surgery along with the recognition of a safe and effective drug delivery system also positively impact the market growth during the forecast years. Besides, the predefined and maintained healthcare regulatory compliance models also aid the high growth of varicella zoster infection treatment.
Increasing focus on reducing the complication of post-herpetic neuralgia also boosts the market growth. However, the availability of alternative treatment including the reliability of natural products, strict regulatory norms for the approval process and the lack of knowledge among people about herpes zoster restricts the market growth. On the contrary, the growing emphasis on the improvement of antiviral drugs coupled with the reduction in the economic burden of VZV infection serves to be the major applicable trend affecting the market growth.
Furthermore, Reports and Insights (R&I) Study elaborates on the study of the Centres of Disease Control and Prevention, which resulted that the transmission of varicella is high among the household members. Besides, more than 90% of the varicella cases are registered due to close contact with people suffering from varicella. Whereas, the varicella transmission rate in schools and daycare centers are lower than 30%–50%. Thus, the growing cases of herpes zoster among the aging population acknowledge being the best market-changing trend during the next decade.
R&I Study identifies some of the key participating players in the varicella zoster infection treatment market globally are Abbott Laboratories, Dr. Reddy’s Laboratories, ltd., GlaxoSmithKline plc., Mylan N.V., Novartis AG, Pfizer Inc., Sun Pharmaceuticals Industries Ltd., Teva Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International Inc.
Reports and Insights (R&I) is committed to provide deep insights that serve as a creative tool for the client that enables it to perform confidently in the market. At R&I we adhere to the client's needs and regularly ponder to bring out more valuable and real outcomes for our customers. We are equipped with a strategically enhanced group of researchers and analysts that redefines and stabilizes the business polarity in different categorical dimensions of the market.
Reports and Insights (R&I)
For Sales Queries: [email protected]
For New Topics and Other Info: [email protected]